First Targeted Therapy for Glioma Headed for FDA Approval
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
The American Brain Tumor Association (ABTA) today announced a new partnership with Brain Tumour Foundation of Canada (BTFC) to accelerate brain tumor research. Through this partnership, BTFC will invest in the ABTA research program to co-fund a research project in Canada, focused on improving resection for low-grade glioma.
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631
